Securian Asset Management Inc Trims Stake in Becton Dickinson and Co (BDX)

Securian Asset Management Inc cut its position in Becton Dickinson and Co (NYSE:BDX) by 0.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,575 shares of the medical instruments supplier’s stock after selling 48 shares during the period. Securian Asset Management Inc’s holdings in Becton Dickinson and were worth $6,213,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BDX. IMS Capital Management acquired a new position in Becton Dickinson and during the 3rd quarter valued at about $29,000. JCIC Asset Management Inc. acquired a new position in Becton Dickinson and during the 4th quarter valued at about $54,000. Signet Investment Advisory Group Inc. acquired a new position in Becton Dickinson and during the 4th quarter valued at about $56,000. Essex Savings Bank acquired a new position in Becton Dickinson and during the 4th quarter valued at about $67,000. Finally, Intercontinental Wealth Advisors LLC acquired a new position in Becton Dickinson and during the 4th quarter valued at about $80,000. Institutional investors own 86.28% of the company’s stock.

Becton Dickinson and stock opened at $242.21 on Monday. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. The company has a market cap of $65.17 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.70 and a beta of 1.23.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the firm earned $2.48 EPS. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, sell-side analysts expect that Becton Dickinson and Co will post 12.1 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.27%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

BDX has been the subject of a number of analyst reports. Citigroup cut their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a research note on Tuesday, November 13th. Wells Fargo & Co cut their price target on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Barclays set a $260.00 price target on Becton Dickinson and and gave the company a “hold” rating in a research note on Thursday, November 8th. UBS Group initiated coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price target for the company. Finally, Deutsche Bank began coverage on Becton Dickinson and in a research note on Thursday, December 6th. They set a “buy” rating and a $280.00 price target for the company. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $253.17.

In related news, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $252.37, for a total value of $1,485,702.19. Following the sale, the executive vice president now owns 6,013 shares of the company’s stock, valued at approximately $1,517,500.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 16,866 shares of Becton Dickinson and stock in a transaction that occurred on Tuesday, November 13th. The stock was sold at an average price of $237.61, for a total transaction of $4,007,530.26. The disclosure for this sale can be found here. Insiders sold a total of 34,606 shares of company stock worth $8,356,772 in the last ninety days. 0.12% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/02/11/securian-asset-management-inc-trims-stake-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Call Option

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply